Research
Hormonal
The protective effect of beneficial dietary components on all-cause mortality is partially mediated by a reduction in systemic inflammation, as measured by the Systemic Inflammation Index (SII).
While reducing inflammation is part of the benefit, it is not the whole story. The dietary components likely work through multiple pathways, including direct gut microbiome effects, not just lowering blood inflammation markers.
GoodQualifiesMEDIUM confidence
The systemic inflammation index (SII) accounted for 5.29% and 8.45% of the observed associations between the total and beneficial DI-GM scores and all-cause mortality, respectively.
Why this rating
Mediation analysis is robustly performed, but the effect size of the mediator is small.
Source
Dietary Index for Gut Microbiota and Risk of All-Cause and Cardiovascular Mortality Across Cardiovascular-Kidney-Metabolic Syndrome Stages 0–3: A Nationwide Prospective Cohort Study
Yifei Wang et al. · Reviews in Cardiovascular Medicine · 2026
DOI 10.31083/rcm45493
cohort · n=7884
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Higher scores on the Dietary Index for Gut Microbiota (DI-GM), specifically driven by beneficial components, are associated with significantly reduced all-cause and cardiovascular mortality in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3.Good
- High unfavorable dietary components (processed meats, red meats, refined grains, high-fat patterns) are associated with increased all-cause mortality but show no significant association with cardiovascular mortality after full adjustment.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →